No antipsychotic is designed to cause weight loss, but a few are consistently linked to minimal weight change or slight weight reduction compared to placebo. Haloperidol, for example, showed an average change of negative 0.23 kg in a large network meta-analysis of 18 antipsychotics, and molindone, an older drug, produced an average loss of 7.6 kg over three months in one clinical study. For most people searching this question, though, the real opportunity for weight loss comes from switching away from a high-gain antipsychotic to one with a more favorable metabolic profile.
Antipsychotics Closest to Weight Neutral
A systematic review published in The Lancet Psychiatry compared the metabolic effects of 18 antipsychotics and found that aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone had the most benign metabolic profiles. None of these reliably causes weight loss on its own when started fresh, but they stand apart from drugs like olanzapine and clozapine, which sit at the opposite end of the spectrum. Clozapine averaged 3.01 kg of weight gain over placebo, and olanzapine produced the largest increase in BMI at 1.07 kg/m² above placebo.
Haloperidol, a first-generation antipsychotic, actually trended slightly below placebo for both weight and BMI. Cariprazine showed the smallest effect on cholesterol of any drug studied, with levels that were essentially unchanged from placebo. These drugs don’t shrink your waistline, but they avoid the metabolic disruption that makes weight management so difficult on other antipsychotics.
Molindone: The One Linked to Actual Weight Loss
Molindone is a first-generation antipsychotic that stands alone in being associated with genuine weight reduction. In a study of nine hospitalized patients with chronic schizophrenia, molindone produced an average weight loss of 7.6 kg (about 16.7 pounds) over three months, with most of the loss occurring in the first month. Researchers suspect molindone has a central appetite-suppressing effect, though the exact mechanism remains unclear.
Molindone is rarely prescribed today. It’s not widely available and lacks the extensive safety and efficacy data that newer drugs have accumulated. Still, it remains a notable exception in a drug class overwhelmingly associated with weight gain.
Weight Loss From Switching Medications
The most practical path to weight loss for someone already on a high-gain antipsychotic is switching to a weight-neutral alternative. The data here is encouraging. A meta-analysis of switching studies found that patients who moved from olanzapine to aripiprazole lost an average of 3.21 kg, and those who switched to quetiapine lost about 1.77 kg. In studies that directly compared “switch versus stay,” patients who switched to aripiprazole lost 5.52 kg more than those who remained on olanzapine.
Ziprasidone also performs well in switching scenarios. Before-and-after analyses found it was associated with a loss of 2.22 kg, while aripiprazole showed a loss of 1.96 kg. Switching to lurasidone, amisulpride, or paliperidone/risperidone didn’t produce significant weight changes in either direction.
A one-year extension of several switch studies found that patients who moved from olanzapine or risperidone to ziprasidone maintained significant weight reduction over the longer term. Those who switched from first-generation antipsychotics, however, did not see the same benefit, likely because those older drugs weren’t causing as much weight gain to begin with.
How Long Weight Loss Takes After a Switch
Most of the clinical data on switching tracks outcomes over 6 to 24 weeks, and weight changes tend to appear within the first few months. Molindone’s effect was concentrated in the first month. For switches to aripiprazole or ziprasidone, meaningful reductions typically show up within the first 8 to 12 weeks, with continued but slower progress over the following months. This is not rapid weight loss. It reflects the body gradually recalibrating once the metabolic burden of the previous drug is removed.
Why Some Antipsychotics Drive Weight Gain
The difference between a weight-gaining and a weight-neutral antipsychotic comes down to how strongly the drug interacts with certain receptors in the brain that regulate appetite, fat storage, and blood sugar. Olanzapine and clozapine bind aggressively to receptors involved in hunger signaling and metabolic regulation, which is why they cause the most dramatic weight gain. Drugs like aripiprazole, ziprasidone, and cariprazine have a much lighter touch on those same receptors, which is why they leave metabolism relatively undisturbed.
This receptor profile also explains why the weight gain from olanzapine and clozapine is not simply about eating more. These drugs can alter how the body processes insulin and stores fat independent of calorie intake, making the weight especially stubborn to lose through diet and exercise alone.
Newer Options With Favorable Profiles
Lumateperone, approved in 2019, has shown a favorable weight profile across multiple clinical trials. A systematic review of three randomized controlled trials and two open-label studies found that lumateperone produced minimal to no weight gain compared with both placebo and other antipsychotics. It represents a newer generation of drugs designed with metabolic side effects in mind from the start.
Another approach targets the weight gain problem directly. A combination of olanzapine with an opioid receptor blocker (sold as Lybalvi) was designed to preserve olanzapine’s strong efficacy while reducing its metabolic impact. In a 24-week trial, patients on the combination gained 2.38% less body weight than those on olanzapine alone. That’s a meaningful reduction for people who need olanzapine’s therapeutic benefits but struggle with its weight effects.
What This Means in Practice
If you’re currently on an antipsychotic and concerned about weight, the most evidence-backed options are aripiprazole and ziprasidone as switch targets, with cariprazine and lurasidone as additional weight-neutral choices. The amount of weight you’re likely to lose depends heavily on which drug you’re coming from. Switching away from olanzapine or clozapine produces the most noticeable results, often in the range of 2 to 5 kg over the first several months.
No antipsychotic should be changed or stopped based on weight alone. The decision involves balancing metabolic risk against psychiatric stability, and abrupt switches can destabilize symptoms. But the metabolic differences between these drugs are real and large enough to matter for long-term cardiovascular health, diabetes risk, and quality of life.